Expand / Collapse search
Watch TV
☰

Quotes displayed in real-time or delayed by at least 15 minutes. Market data provided by Factset. Powered and implemented by FactSet Digital Solutions.  Legal Statement.

This material may not be published, broadcast, rewritten, or redistributed. ©2026 FOX News Network, LLC. All rights reserved. FAQ - New Privacy Policy

opko health inc. - OPK

OPK

Close Chg Chg %
1.36 0.01 0.74%

Closed Market

1.37

+0.01 (0.74%)

Volume: 2.43M

Last Updated:

Jan 8, 2026, 4:00 PM EDT

Trade Now

Company Overview: opko health inc. - OPK

OPK Key Data

Open

$1.35

 Day Range

1.34 - 1.38

52 Week Range

1.11 - 2.04

 Market Cap

$1.01B

Shares Outstanding

767.70M

 Public Float

391.08M

Beta

1.39

 Rev. Per Employee

N/A

P/E Ratio

N/A

 EPS

-$0.24

Yield

0.00%

 Dividend

N/A

EX-DIVIDEND DATE

SHORT INTEREST

N/A

AVERAGE VOLUME

3.73M

  

OPK Performance

1 Week
 
 8.73%
 
1 Month
 
 -0.72%
 
3 Months
 
 -9.27%
 
1 Year
 
 -6.80%
 
5 Years
 
 -68.86%
 

OPK Analyst Ratings

  • Sell
  • Under
  • Hold
  • Over
  • Buy
Number of Ratings 7
Full Ratings ➔

About opko health inc. - OPK

OPKO Health, Inc. is a biopharmaceutical and diagnostics company, which engages in the provision of healthcare services. It operates through the following segments: Diagnostics and Pharmaceuticals. The Diagnostics segment includes the clinical laboratory operations of BioReference, as well as point-of-care operations. The Pharmaceuticals segment includes pharmaceutical operations in Chile, Mexico, Ireland, Israel, and Spain and pharmaceutical research and development operations. The company was founded in October 1991 and is headquartered in Miami, FL.

OPK At a Glance

OPKO Health, Inc.
4400 Biscayne Boulevard
Miami, Florida 33137
Phone 1-305-575-4100 Revenue 713.14M
Industry Medical/Nursing Services Net Income -53,224,000.00
Sector Health Services Employees 2,997
Fiscal Year-end 12 / 2025
View SEC Filings

OPK Valuation

P/E Current N/A
P/E Ratio (with extraordinary items) N/A
P/E Ratio (without extraordinary items) N/A
Price to Sales Ratio 1.431
Price to Book Ratio 0.723
Price to Cash Flow Ratio N/A
Enterprise Value to EBITDA -6.23
Enterprise Value to Sales 1.532
Total Debt to Enterprise Value 0.462

OPK Efficiency

Revenue/Employee 237,951.952
Income Per Employee -17,759.092
Receivables Turnover 4.69
Total Asset Turnover 0.339

OPK Liquidity

Current Ratio 3.429
Quick Ratio 3.135
Cash Ratio 2.237

OPK Profitability

Gross Margin 19.053
Operating Margin -38.36
Pretax Margin -1.453
Net Margin -7.463
Return on Assets -2.527
Return on Equity -3.864
Return on Total Capital -2.846
Return on Invested Capital -3.03

OPK Capital Structure

Total Debt to Total Equity 36.943
Total Debt to Total Capital 26.977
Total Debt to Total Assets 22.927
Long-Term Debt to Equity 34.794
Long-Term Debt to Total Capital 25.408
  • Income Statement
  • Balance Sheet
  • Cash Flow Statement

Annual Financials for Opko Health Inc. - OPK

Collapse All in section
All values USD millions. 2021 2022 2023 2024 5-year trend
Sales/Revenue
1.77B 1.00B 863.50M 713.14M
Sales Growth
+23.64% -43.42% -14.01% -17.41%
Cost of Goods Sold (COGS) incl D&A
1.24B 799.70M 631.40M 577.27M
COGS excluding D&A
- - - -
-
Depreciation & Amortization Expense
78.72M 108.66M 105.30M 98.18M
Depreciation
28.44M 20.87M 19.27M 15.54M
Amortization of Intangibles
50.28M 87.78M 86.03M 82.63M
COGS Growth
+30.71% -35.35% -21.05% -8.57%
Gross Income
537.71M 204.49M 232.09M 135.88M
Gross Income Growth
+9.96% -61.97% +13.50% -41.46%
Gross Profit Margin
+30.30% +20.36% +26.88% +19.05%
2021 2022 2023 2024 5-year trend
SG&A Expense
545.71M 446.56M 390.15M 409.43M
Research & Development
76.85M 73.89M 89.59M 105.21M
Other SG&A
468.86M 372.67M 300.56M 304.22M
SGA Growth
+26.65% -18.17% -12.63% +4.94%
Other Operating Expense
- - 6.46M 4.06M
-
Unusual Expense
13.38M 152.52M 277.00K 6.31M
EBIT after Unusual Expense
(27.84M) (398.64M) (158.33M) (279.87M)
Non Operating Income/Expense
32.69M 19.18M (12.48M) 316.98M
Non-Operating Interest Income
28.00K 1.98M 3.98M 8.43M
Equity in Earnings of Affiliates
- - - -
-
Interest Expense
18.88M 12.06M 13.51M 47.47M
Interest Expense Growth
-13.92% -36.14% +12.03% +251.44%
Gross Interest Expense
18.88M 12.06M 13.51M 47.47M
Interest Capitalized
- - - -
-
Pretax Income
(14.03M) (391.52M) (184.32M) (10.36M)
Pretax Income Growth
-128.81% -2,691.39% +52.92% +94.38%
Pretax Margin
-0.79% -38.99% -21.35% -1.45%
Income Tax
15.49M (63.50M) 4.44M 42.84M
Income Tax - Current - Domestic
2.54M 394.00K (459.00K) 24.43M
Income Tax - Current - Foreign
2.79M 10.51M 4.75M 3.67M
Income Tax - Deferred - Domestic
9.62M (52.83M) (246.00K) 24.91M
Income Tax - Deferred - Foreign
538.00K (21.58M) 392.00K (10.17M)
Income Tax Credits
- - - -
-
Equity in Earnings of Affiliates
- - - -
-
Other After Tax Income (Expense)
- - - -
-
Consolidated Net Income
(30.14M) (328.40M) (188.86M) (53.22M)
Minority Interest Expense
- - - -
-
Net Income
(30.14M) (328.40M) (188.86M) (53.22M)
Net Income Growth
-198.55% -989.49% +42.49% +71.82%
Net Margin Growth
-1.70% -32.70% -21.87% -7.46%
Extraordinaries & Discontinued Operations
- - - -
-
Discontinued Operations
- - - -
-
Net Income After Extraordinaries
(30.14M) (328.40M) (188.86M) (53.22M)
Preferred Dividends
- - - -
-
Net Income Available to Common
(30.14M) (328.40M) (188.86M) (53.22M)
EPS (Basic)
-0.0465 -0.4567 -0.2512 -0.0767
EPS (Basic) Growth
-197.48% -882.15% +45.00% +69.47%
Basic Shares Outstanding
648.08M 719.06M 751.77M 694.02M
EPS (Diluted)
-0.0465 -0.4567 -0.2512 -0.0767
EPS (Diluted) Growth
-197.48% -882.15% +45.00% +69.47%
Diluted Shares Outstanding
648.08M 719.06M 751.77M 694.02M
EBITDA
64.25M (137.47M) (52.76M) (175.38M)
EBITDA Growth
-53.80% -313.94% +61.62% -232.41%
EBITDA Margin
+3.62% -13.69% -6.11% -24.59%

Snapshot

Average Recommendation OVERWEIGHT Average Target Price 3.625
Number of Ratings 7 Current Quarters Estimate -0.06
FY Report Date 03 / 2026 Current Year's Estimate -0.259
Last Quarter’s Earnings -0.07 Median PE on CY Estimate N/A
Year Ago Earnings -0.332 Next Fiscal Year Estimate -0.14
Median PE on Next FY Estimate N/A

Earnings Per Share

This Quarter Next Quarter This Fiscal Next Fiscal
# of Estimates 5 5 7 3
Mean Estimate -0.06 -0.06 -0.26 -0.14
High Estimates -0.03 -0.03 -0.13 -0.07
Low Estimate -0.08 -0.08 -0.41 -0.25
Coefficient of Variance -33.33 -33.16 -34.04 -68.88

Analysts Recommendations

Current 1 Month Ago 3 Months Ago
BUY 5 5 5
OVERWEIGHT 0 0 0
HOLD 2 2 1
UNDERWEIGHT 0 0 0
SELL 0 0 0
MEAN Overweight Overweight Buy

Insider Actions for Opko Health Inc. - OPK

Date Name Shares Transaction Value
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,386,858 Open market or private purchase of non-derivative security Non-derivative transaction at $1.24 per share 265,839,703.92
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,436,448 Open market or private purchase of non-derivative security Non-derivative transaction at $1.25 per share 268,045,560.00
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,503,083 Open market or private purchase of non-derivative security Non-derivative transaction at $1.26 per share 270,273,884.58
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,549,783 Grant, award or other acq pursuant to Rule 16b-3(d) Non-derivative transaction at $1.26 per share 270,332,726.58
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,564,783 Open market or private purchase of non-derivative security Non-derivative transaction at $1.26 per share 270,351,626.58
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,566,555 Open market or private purchase of non-derivative security Non-derivative transaction at $1.27 per share 272,499,524.85
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,779,163 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 274,917,328.64
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,848,891 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 275,006,580.48
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,849,319 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 275,007,128.32
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,932,875 Open market or private purchase of non-derivative security Non-derivative transaction at $1.28 per share 275,114,080.00
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,932,876 Open market or private purchase of non-derivative security Non-derivative transaction at $1.29 per share 277,263,410.04
Nov 20, 2025 Phillip Frost CEO & Chairman; Director 214,966,448 Open market or private purchase of non-derivative security Non-derivative transaction at $1.29 per share 277,306,717.92

Opko Health Inc. in the News